Legal Advantage Investments Inc. Acquires 1,000 Shares of Johnson & Johnson (NYSE:JNJ)

Legal Advantage Investments Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 62.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,596 shares of the company’s stock after purchasing an additional 1,000 shares during the quarter. Legal Advantage Investments Inc.’s holdings in Johnson & Johnson were worth $375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Fred Alger Management LLC lifted its holdings in shares of Johnson & Johnson by 6.1% during the second quarter. Fred Alger Management LLC now owns 42,968 shares of the company’s stock valued at $6,280,000 after purchasing an additional 2,488 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 38.6% during the second quarter. AQR Capital Management LLC now owns 3,350,292 shares of the company’s stock valued at $489,176,000 after purchasing an additional 932,477 shares during the last quarter. Ameriprise Financial Inc. increased its position in shares of Johnson & Johnson by 5.5% during the second quarter. Ameriprise Financial Inc. now owns 14,374,397 shares of the company’s stock valued at $2,100,427,000 after acquiring an additional 754,200 shares in the last quarter. Drucker Wealth 3.0 LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $612,000. Finally, Daymark Wealth Partners LLC increased its position in shares of Johnson & Johnson by 2.0% during the second quarter. Daymark Wealth Partners LLC now owns 304,204 shares of the company’s stock valued at $44,462,000 after acquiring an additional 6,033 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.9 %

Shares of JNJ stock opened at $146.58 on Friday. The stock has a market cap of $352.91 billion, a P/E ratio of 21.21, a PEG ratio of 2.52 and a beta of 0.51. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The company’s fifty day simple moving average is $148.10 and its two-hundred day simple moving average is $156.05.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. Analysts predict that Johnson & Johnson will post 9.95 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday. Wells Fargo & Company cut their target price on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday. Bank of America cut their target price on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Guggenheim lifted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Nine analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $170.06.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.